Research Guide

On January 27, 1964, Academician Lu Daopei, the "founder of bone marrow transplantation in China," successfully performed Asia's first and the world's fourth allogeneic bone marrow transplantation at Peking University People's Hospital. This opened the era of hematopoietic stem cell transplantation (HSCT) for treating hematological diseases in China, bringing new hope to countless hematology patients.

Zhou Zhou from Guangxi is a patient with severe β-thalassemia. After 16 years of blood transfusion, she and her family decided to undergo hematopoietic stem cell transplantation (HSCT). In 2021, the soon-to-be 17-year-old Zhou Zhou found the team led by Director Liao Jianyun. After two years of continuous iron chelation therapy, she underwent HSCT at Southern Chunfu (Children's) Institute of Hematology, Gobroad Medical (Hematology) Guangdong Research Center in 2023.

Team of Academician Wang Jian'an from the Second Affiliated Hospital of Zhejiang University Successfully Performed Two Transcatheter Edge-to-Edge Mitral Valve Repair Surgeries at the National Medical Research Center for Cardiology of the Russian Federation

The procedure was performed percutaneously under DSA and ICE guidance. Post-procedure ultrasound confirmed the bioabsorbable PFO occluder had good morphology and position, complete closure with no residual shunt, no pericardial effusion, and no adverse reactions before or after closure, indicating successful closure.

In pursuit of proton therapy, Mr. C came to Guangzhou Concord Cancer Center . During examinations, abnormal thickening of his rectal wall was also discovered. Further colonoscopy and pathology results ultimately confirmed he had a second primary cancer: a rectosigmoid junction tumor.

One month ago, Ms. Li began experiencing symptoms including numbness on the left side of her face, veering to the left while walking, and occasional choking while eating. The progression of the disease caused Ms. Li significant anxiety, leading her to return to the Neurosurgery Department at Beijing Tiantan Puhua Hospital.

Ms. Zhu never imagined that at the age of 84, she would undergo such a "record-breaking" surgery. Doctors removed her entire pancreas, spleen, and gallbladder, reconstructed her gastrointestinal tract and blood vessels, and simultaneously performed an autologous islet transplantation.

CyberKnife is the world's first automated robotic radiosurgery system, perfectly embodying Stereotactic Body Radiotherapy (SBRT) principles. It delivers high-precision, personalized treatment solutions suitable for most solid tumors throughout the body.

Orlando, USA, Dec 6-9, 2025 – The 67th American Society of Hematology (ASH) Annual Meeting, one of the most influential global hematology events, convened top scholars and clinical experts from over 100 countries. The meeting served as a premier platform for exchanging groundbreaking research, diagnostic and treatment concepts, and practical experience, collectively shaping the future of hematology.

CyberKnife is the world's first automated robotic radiosurgery system, perfectly embodying Stereotactic Body Radiotherapy (SBRT) principles. It delivers high-precision, personalized treatment solutions suitable for most solid tumors throughout the body.

A Belgian MS patient, Alex, regained his life after CAR-T therapy in China - from wheelchair-bound to walking and embracing his child again. Huazhong University's Professor Wang Wei team pioneered the breakthrough, proving CAR-T can safely cross the blood-brain barrier to clear pathogenic B cells in CNS. Published in Cell, this marks a milestone in autoimmune disease treatment.

CAR-T therapy, the 4th major cancer treatment, engineers patient's T cells to target cancers. Highly effective for blood cancers like leukemia & lymphoma. Promising for solid tumors & non-cancer diseases. Faces challenges like cost & side effects, but research is advancing rapidly.

Lu Daopei Hospital's dual-target CAR-T saves critically ill international DLBCL patient! A 60-year-old Egyptian with massive abdominal tumor & TP53 mutations achieved remarkable recovery after CD19/CD22 CAR-T + radiotherapy. From unable to sit to walking out smiling.

Recently, the international hematology journal Blood Advances published a prospective clinical study by Lu Daopei Medical Team, titled "Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma," reporting breakthrough clinical results of BCMA-targeted nanobody-based CAR-T cell therapy in heavily pretreated refractory/relapsed plasma cell neoplasms.

Gynecomastia is the benign enlargement of male breast tissue, caused by estrogen-androgen imbalance. Common in infants, teens, and older men, it can involve glandular tissue, fat, or both. While often a cosmetic concern, it may cause distress. Treatments include medication or surgery (liposuction/excision) if persistent. Effective correction is achievable.

Gynecomastia: Understanding Male Breast Development Gynecomastia, or male breast enlargement, stems from estrogen-testosterone imbalance. Causes include puberty, obesity, medications, or underlying conditions. Diagnosis involves physical exams, hormone tests, or ultrasound. Treatments range from addressing root causes to medication or minimally invasive surgery. Many seek correction for confidence. Consult a specialist for personalized care.

Relapsed/Refractory Diffuse Large B-Cell Lymphoma - A Breakthrough in CD20 CAR-T Preemptive Therapy. the team of Directors Ke Xiaoyan and Hu Kai from the Department of Lymphoma and Myeloma at Beijing Gobroad Hospital published a study titled "CD20 CAR-T Therapy Preemptively Treats Patients with Relapsed/Refractory DLBCL in Partial Remission after CD19 CAR-T" in the journal Transplant and Cellular Therapy.